Target Name: USP17L7
NCBI ID: G392197
Review Report on USP17L7 Target / Biomarker Content of Review Report on USP17L7 Target / Biomarker
USP17L7
Other Name(s): Ubiquitin specific peptidase 17 like family member 7 | Inactive ubiquitin carboxyl-terminal hydrolase 17-like protein 7 | U17L7_HUMAN | ubiquitin specific peptidase 17 like family member 7 | ubiquitin specific peptidase 17-like 7 | Ubiquitin specific peptidase 17-like 7

USP17L7: A Potential Drug Target and Biomarker for Ubiquitin Specific Peptidase 17-Like Family Member 7

Introduction

Ubiquitin specific peptidase 17-like family member 7 (USP17L7) is a protein that plays a crucial role in the regulation of protein degradation in the body. It is a member of the ubiquitin-proteasome system (UPS), which is responsible for removing damaged or unnecessary proteins from the cell. USP17L7 is involved in the degradation of a wide variety of proteins, including caseins, which are important for muscle growth and development.

Despite its importance, USP17L7 has been until now, overlooked as a potential drug target or biomarker. However, recent studies have identified potential targets for USP17L7, which may reveal its true potential as a drug. In this article, we will explore the biology and potential drug targets of USP17L7.

The biology of USP17L7

USP17L7 is a 23-kDa protein that is expressed in various tissues, including muscle, heart, and brain. It is a single-pass protein that belongs to the Ubiquitin specific peptidase 17-like family member 7. This family includes a variety of proteins that share a conserved catalytic core and a specific structural domain, known as the 尾-sheet.

USP17L7 is involved in the degradation of a wide variety of proteins, including caseins, which are important for muscle growth and development. It has also been shown to interact with caseins and to play a role in the regulation of protein degradation. to interact with the proteinBeclin-1 (Bec1), which is involved in cell signaling and is a known regulator of USP17L7.

Potential drug targets for USP17L7

Several studies have identified potential drug targets for USP17L7. One of the most promising targets is the protein known as Z-DNA, which is a component of the chromatin complex. USP17L7 has been shown to interact with Z-DNA and has been proposed as a potential drug target for the treatment of various diseases, including cancer.

Another potential drug target for USP17L7 is the protein known as p120G, which is a component of the endoplasmic reticulum (ER) and is involved in protein degradation. USP17L7 has been shown to interact with p120G and has been proposed as a potential drug target for the treatment of various diseases, including neurodegenerative disorders.

Biomarkers for USP17L7

USP17L7 has also been identified as a potential biomarker for several diseases. For example, USP17L7 has been shown to be involved in the regulation of muscle growth and development, and has been proposed as a potential biomarker for muscle-related diseases, such as dystopian muscle diseases and myopathies.

USP17L7 has also been shown to be involved in the regulation of protein degradation, which is a critical process for the maintenance of cellular homeostasis. This makes it a potential biomarker for diseases that are characterized by the accumulation of damaged or unnecessary proteins, such as neurodegenerative disorders.

Conclusion

In conclusion, USP17L7 is a protein that plays a crucial role in the regulation of protein degradation in the body. Its potential as a drug target or biomarker has been identified, and further studies are needed to fully understand its biology and clinical potential.

Protein Name: Ubiquitin Specific Peptidase 17 Like Family Member 7

The "USP17L7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about USP17L7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

USP17L8 | USP17L9P | USP18 | USP19 | USP2 | USP2-AS1 | USP20 | USP21 | USP22 | USP24 | USP25 | USP26 | USP27X | USP27X-DT | USP28 | USP29 | USP3 | USP3-AS1 | USP30 | USP30-AS1 | USP31 | USP32 | USP32P1 | USP32P2 | USP32P3 | USP33 | USP34 | USP35 | USP36 | USP37 | USP38 | USP39 | USP4 | USP40 | USP41 | USP42 | USP43 | USP44 | USP45 | USP46 | USP46-DT | USP47 | USP48 | USP49 | USP5 | USP50 | USP51 | USP53 | USP54 | USP6 | USP6NL | USP6NL intronic transcript 1 (non-protein coding), transcript variant 1 | USP7 | USP8 | USP8P1 | USP9X | USP9Y | USPL1 | UST | UTF1 | UTP11 | UTP14A | UTP14C | UTP15 | UTP18 | UTP20 | UTP23 | UTP25 | UTP3 | UTP4 | UTP6 | UTRN | UTS2 | UTS2B | UTS2R | UTY | UVRAG | UVSSA | UXS1 | UXT | UXT-AS1 | VAC14 | Vacuolar H+ ATPase | VAMP1 | VAMP2 | VAMP3 | VAMP4 | VAMP5 | VAMP7 | VAMP8 | VANGL1 | VANGL2 | VAPA | VAPB | VARS1 | VARS2 | Vascular endothelial growth factor receptor (VEGFR) | Vascular endothelial growth factors (VEGF) | VASH1 | VASH1-AS1